GlyCardial was born from the passion for research and to translate a discovery made in the laboratory into a solution that could help to reduce the impact of cardiovascular disease on patients' life.
Not only because of the potential social impact of iSCOR, but also towards all our partners that are helping us to get closer to our goal.
The technology is based on the detection of glycosylated Apolipoprotein J (ApoJ-Glyc) in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patients' evolution after an ischemic event.
2017
Development of assay in ELISA format
Identification of monoclonal antibodies
2018
Retrospective clinical validation
Validation in experimental studies
2019
EDICA Multicenter Prospective Clinical Trial
Recruitment of patients
2020
Assay verification and validation
2021
EDICA trial follow-up
Additional uses of ApoJ-Glyc
2022-2023
iSCOR validated in an agnostic assay format
Fast-test development